Cell and gene therapy

Paris
#Cell and gene therapy #Events #ISCT #Mesenchymal stem cells #new generation MSCs

ISCT 2023 key trends: new generation MSCs  

The International Society for Cellular Therapy (ISCT) is a global society of clinicians, regulators, technologists, and industry partners with a shared mission to drive the translation of all cell and gene (CGT) therapies for the benefit of patients worldwide. The ISCT 2023 Annual Meeting took place in Paris, France from… Read More

#Exclusive Content

#Autolomous #Cell and gene therapy #Cell and Gene Therapy Catapult #Digitalisation #Funding

CGT grant funds implementation and digitisation of PAT  

Autolomous, a developer of critical manufacturing management systems for cell and gene therapies (CGTs), and the Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in the advancement of CGTs, have been awarded a joint £1.2 million grant by UK Research and Innovation (UKRI),… Read More

#News

#Automation / robotics #Cell and gene therapy #Cellular Origins #ISCT

Robotic platform to enable scalable manufacture of advanced therapies 

Cellular Origins, a company focused on enabling scalable, cost-effective and space-efficient manufacture of cell and gene therapies (CGTs), has launched Constellation, its closed, configurable, robotic platform at the International Society for Cell and Gene Therapy (ISCT) Annual Meeting 2023.   Designed to automate the manufacturing of advanced therapies… Read More

#News

Paris
#allogeneic cell therapies #Cell and gene therapy #Events #ISCT

ISCT 2023 key trends: Allo vs Auto 

The International Society for Cellular Therapy (ISCT) is a global society of clinicians, regulators, technologists, and industry partners with a shared mission to drive the translation of all cell and gene (CGT) therapies for the benefit of patients worldwide. The ISCT 2023 Annual Meeting took place in Paris, France from… Read More

#Exclusive Content

CGTC Edinburgh lab
#Cell and gene therapy #Cell and Gene Therapy Catapult #CGT Catapult #Edinburgh BioQuarter #Lab technology

Cell and Gene Therapy Catapult opens new Scottish laboratories 

The Cell and Gene Therapy Catapult (CGT Catapult) has opened its facility in the Edinburgh BioQuarter, its first site in Scotland.   By opening these new laboratories, the CGT Catapult aims to provide expertise, resources and technology to help cell therapy developers improve their manufacturing processes and navigate… Read More

#News

Paris
#Cell and gene therapy #Cell collections #Events #ISCT

ISCT 2023 key trends: the importance of cell collections 

The International Society for Cellular Therapy (ISCT) is a global society of clinicians, regulators, technologists, and industry partners with a shared mission to drive the translation of all cell and gene therapies for the benefit of patients worldwide. The ISCT 2023 Annual Meeting took place in Paris, France from May… Read More

#Exclusive Content

Drug discovery
#Antibody drug conjugate (ADC) #Artificial intelligence (AI) #Cell and gene therapy #Drug development #Drug discovery #mRNA-based vaccines #Roundtable

Exclusive roundtable on drug discovery and development trends

Hosted by DDW and sponsored by DNA Script, ‘Drug discovery and development trends – what will have most impact?’ will be free to attend on June 28 at 8AM PT | 11AM ET | 4PM BST | 5PM CET. Join this free roundtable… Read More

Webinar date:
Sponsored by DNA Script
#News

Drug discovery
#Antibody drug conjugate (ADC) #Artificial intelligence (AI) #Cell and gene therapy #Drug development #Drug discovery #mRNA-based vaccines

Drug discovery and development trends – what will have most impact?

Hosted by DDW and sponsored by DNA Script, watch this free roundtable on demand to learn about the biggest opportunities for the future of drug discovery and development. Roundtable panellists include Commercial Research Scientist, Dr Mark Treherne, CEO of Elevation Oncology, Joe Ferra, and CEO of BioXcel… Read More

Webinar date:
Sponsored by DNA Script
#Webinars

Innovation
#Advanced Therapies #Animal models #Autoimmune disease #Cell and gene therapy #Data #Genetics / genomics #Immunology #Pharma

New podcast on animal genomics, immunology and CGTs

This is the latest episode of the free DDW narrated podcast, “What’s at the forefront of innovation?” It covers three articles written for the for Volume 23, Issue 2 – Spring 2022 of DDW. They are called “Can animal genomics help find… Read More

#News

Lipid nanoparticle mRNA vaccine
#Advanced Therapies #Cell and gene therapy #Moderna #mRNA #Phase II trial #Rare disease

Positive initial data on first mRNA therapy for propionic acidemia

Moderna has reported encouraging interim data from its Phase I/II trial of mRNA-3927, an mRNA therapy for rare metabolic disorder propionic acidemia (PA). The data was presented at the 2023 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. The ongoing global Phase… Read More

#News #Trending News

#Advanced Therapies #Cell and gene therapy #Cell therapy #Gene therapy

Under the microscope: Zoning in on the CGT sector

Listen to this article on the DDW Podcast: IB Communications’ CEO Michelle Boxall explains why there are two sides to the cell and gene therapy coin. Charles Dickens’ quote, “It was the best of times, it was the worst of times”, aptly describes the complexity surrounding CGT financing. With 2023’s financial… Read More

#Exclusive Content #Opinion

DNA vector
#Cell and gene therapy #FDA #Gene therapy #Muscular dystrophy #Sarepta Therapeutics

FDA committee supports gene therapy for muscular dystrophy

The US Food and Drug Administration (FDA) Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) have voted eight to six in favour of a new gene therapy for Duchenne muscular dystrophy. The vote supports the accelerated approval of Sarepta Therapeutics’ SRP-9001 (delandistrogene moxeparvovec) for the treatment of ambulatory patients with… Read More

#News #Regulatory #Trending News

#Advanced Therapies #Cell and gene therapy #Cell therapy #Gene therapy

Understanding the future roadmaps of cell and gene therapy

Listen to this article on the DDW Podcast: DDW’s Megan Thomas caught up with George White, General Manager, Product Management, Cell & Gene Therapy at Cytiva, to learn more about the company’s insight into the CGT market. Key challenges for cell and gene therapies In order for cell and gene (CGT) therapies… Read More

#Exclusive Content #Opinion

#Advanced Therapies #CAR-T #Cell and gene therapy #Cell therapy #Gene therapy

No sign of stopping: The rise of cell and gene therapy

Listen to this article on the DDW Podcast: Ryan Leahy, a science communication expert in cell and gene therapy, at Phacilitate, says there is a lot to celebrate but also much to assess, question and challenge in this sector. While the global economic landscape faces a major crisis and biotech is… Read More

#Exclusive Content #Opinion

#Advertorial #Astrea Bioseparations #Bioprocessing #Cell and gene therapy #Nanofiber technology

Nanofiber technology enabling the future of CGT bioprocessing

This paid-for advertorial by Astrea Bioseparations appeared in DDW Volume 24 – Issue 1, Winter 2022/2023 - Cell and Gene Therapy Guide. Therapeutic developers face significant challenges in purifying cell and gene therapy (CGT) modalities. Current processes rely on solutions developed for monoclonal antibodies that are not fit for purpose… Read More

#Exclusive Content

#Cell and gene therapy #Lab automation

Collaboration to simplify cell therapy manufacturing 

Cellular Origins, a company focused on enabling scalable and efficient manufacture of cell and gene therapies (CGTs), has announced a collaborative partnership with ScaleReady, a joint venture between Bio-Techne, Fresenius Kabi and Wilson Wolf that brings together process development expertise, tools and technologies for scalable CGT manufacturing.  … Read More

#News